title: Abietic acid has an anti-obesity effect in mice fed a high-fat diet.
abstract: We investigated the anti-obesity effect of abietic acid in mice fed a high-fat diet with emphasis on changes in adipogenesis in epididymal adipose tissues. Male C57BL/6J mice were divided into four groups and fed a normal diet, a high-fat diet (HFD), or HFD plus oral administration of abietic acid (20 mg/kg of body weight/day [LA] or 40 mg/kg of body weight/day [HA]) for 8 weeks. Compared with the HFD group, mice orally administered 40 mg of abietic acid/kg of body weight/day exhibited significantly decreased body weight and adipose tissue weights. Serum triglyceride concentrations in the HA group were significantly lower than those in the HFD group, as were the levels of serum insulin and leptin. Hematoxylin and eosin staining revealed that epididymal adipose tissue mass was decreased by abietic acid administration. Abietic acid also inhibited the protein expression of sterol regulatory element-binding protein-1c, CCAAT/enhancer-binding protein α, and CD36 in epididymal adipose tissues, which are up-regulated by HFDs. These data demonstrate that abietic acid has an anti-obesity effect in mice mediated by the regulation of adipogenesis.
authors.affiliation: Functional Food Technology Research Group, Korea Food Research Institute, Seongnam, Korea.
authors.forename: Kwang-Hyun
authors.initials: KH
authors.lastname: Hwang
authors.forename: Ji-Yun
authors.initials: JY
authors.lastname: Ahn
authors.forename: Suna
authors.initials: S
authors.lastname: Kim
authors.forename: Jae-Ho
authors.initials: JH
authors.lastname: Park
authors.forename: Tae-Youl
authors.initials: TY
authors.lastname: Ha
mesh_terms: D045784:Abietanes / Q000008:administration & dosage / Q000627:therapeutic use*; D050156:Adipogenesis / Q000187:drug effects; D052436:Adipose Tissue, White / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D050154:Adiposity; D000818:Animals; D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D022763:CCAAT-Enhancer-Binding Protein-alpha / Q000378:metabolism; D018955:CD36 Antigens / Q000378:metabolism; D004041:Dietary Fats / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000097:blood; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009765:Obesity / Q000097:blood / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D011897:Random Allocation; D051780:Sterol Regulatory Element Binding Protein 1 / Q000378:metabolism; D014280:Triglycerides / Q000097:blood; D015430:Weight Gain / Q000187:drug effects
chemical_list: D045784:Abietanes; D019440:Anti-Obesity Agents; D022763:CCAAT-Enhancer-Binding Protein-alpha; D018955:CD36 Antigens; D004041:Dietary Fats; D007328:Insulin; D020738:Leptin; C497388:Srebf1 protein, mouse; D051780:Sterol Regulatory Element Binding Protein 1; D014280:Triglycerides; C023710:abietic acid